Cytotoxic drugs that are mechanistically distinct from current
chemotherapies are attractive components of personalized combination regimens for combatting aggressive forms of
cancer. To gain insight into the cellular mechanism of a potent
platinum-
acridine anticancer agent (compound 1), a correlation analysis of NCI-60 compound screening results and gene expression profiles was performed. A plasma membrane transporter, the solute carrier (SLC) human multidrug and toxin extrusion
protein 1 (hMATE1, SLC47A1), emerged as the dominant predictor of
cancer cell chemosensitivity to the hybrid agent (Pearson correlation analysis, p < 10-5) across a wide range of tissues of origin. The crucial role of hMATE1 was validated in
lung adenocarcinoma cells (A549), which expresses high levels of the
membrane transporter, using transporter inhibition assays and transient knockdown of the SLC47A1 gene, in conjunction with quantification of intracellular accumulation of compound 1 and cell viability screening. Preliminary data also show that HCT-116
colon cancer cells, in which hMATE1 is epigenetically repressed, can be sensitized to compound 1 by priming the cells with the drugs
EPZ-6438 (
tazemetostat) and
EED226. Collectively, these results suggest that hMATE1 may have applications as a pan-
cancer molecular marker to identify and target
tumors that are likely to respond to
platinum-
acridines.